Nighat Sarwar, MD
Neurology · Fresno, CANPI 1003809989
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Biogen accounts for 61.5% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $27,550 and has fallen 66.1% since, to $9,348 in 2025. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,835 payments — averaging $69.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$78K
- EMD Serono, Inc.$10K
- AstraZeneca$5K
- Sanofi$4K
- AbbVie$3K
- Novartis$3K
- plus $24K from 54 others
What the payments were for
- Consulting fees$26,05421%
- Speaking & faculty fees$57,98046%
- Travel & lodging$5,8745%
- Food & beverage$36,46729%
- Education$2570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$126,632 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 25 | $296,496 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $290,035 |
| VumerityDiroximel Fumarate | 26 | $215,562 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 11 | $206,584 |
| NuplazidPimavanserin Tartrate | 30 | $192,810 |
| CopaxoneGlatiramer Acetate | 20 | $138,474 |
| BetaseronInterferon Beta-1b | 14 | $122,066 |
| TysabriNatalizumab | 12 | $96,236 |
| Glatiramer Acetate | 30 | $73,546 |
| RytaryCarbidopa/Levodopa | 53 | $67,075 |
| RexultiBrexpiprazole | 43 | $58,834 |
| BotoxOnabotulinumtoxina | 40 | $50,904 |
| XcopriCenobamate | 18 | $34,982 |
| KeppraLevetiracetam | 29 | $32,753 |
| NeuproRotigotine | 32 | $32,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Tysabri | $77,857 | $311,79838 claims |
| CSL BehringPrivigen | $147 | $290,03513 claims |
| PfizerOctagam, Dilantin | $597 | $208,45423 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,432 | $192,81030 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $1,424 | $138,47420 claims |
| AbbVieBotox, Namzaric | $2,916 | $71,35863 claims |
| Amneal Pharmaceuticals LLCRytary | $541 | $67,07553 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $362 | $58,83443 claims |
| UCB, Inc.Neupro, Vimpat | $1,345 | $54,17452 claims |
| SK Life Science, Inc.Xcopri | $672 | $34,98218 claims |
| AstraZenecaBrilinta | $4,829 | $5,52713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.
Other neurology in Fresno
- Eric FarbmanFresno$866K
- Perminder BhatiaFresno$279K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.